Omeprazol Tecnigen (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of gastric parietal cells. By blocking this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing mucosal healing and symptom relief.

Adverse reactions to omeprazole are generally dose‑related and may vary in frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Vitamin B12 deficiency with long‑term therapy.
• Bone fractures linked to chronic use.
• Acute interstitial nephritis.

When prescribing omeprazole, clinicians should consider several safety aspects.

• Assess renal and hepatic function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: watch for nutrient deficiencies and bone health.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Elderly patients: start at the lowest effective dose and monitor for adverse effects.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation parameters.
• Methotrexate: reduced renal clearance, watch for toxicity.
• Digoxin: increased serum concentrations, assess cardiac status.
• Phenytoin: altered metabolism, monitor seizure control.
• Iron salts: decreased absorption, separate dosing times.